ArticleBMJ open diabetes research & care2025
Performance of an individualized, subcutaneous, basal-bolus insulin regimen for the management of prednisolone-associated hyperglycemia in hospitalized patients: a proof-of-concept study.
Article in BMJ open diabetes research & care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A clinician's guide to corticosteroid therapy in pneumonia and critical illness: agent selection, dosing, monitoring, and interactions.Pneumonia (Nathan Qld.) · 2026Review
- Glucocorticoid-Induced Hyperglycaemia in Hospital: The Insulin Dose Matters Most.Diabetes, obesity & metabolism · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPrednisolone is widely prescribed to hospitalized patients for a range of conditions. Up to 40% of hospitalized patients treated with prednisolone will experience hyperglycemia. Current guidelines recommend management of acute hyperglycemia in hospitalized patients with subcutaneous basal-bolus insulin (BBI), but the optimum treatment strategy has not been defined. We aimed to assess the performance of an individualized subcutaneous BBI regimen for management of prednisolone-associated hyperglycemia in hospitalized patients. RESEARCH DESIGN AND
methodsThis cross-sectional study included 23 adult inpatients prescribed subcutaneous BBI based on total daily insulin requirements estimated from a 24-hour intravenous insulin infusion and 24 historical controls who were prescribed a standard, institutional weight-based subcutaneous BBI to treat prednisolone-associated hyperglycemia. The primary endpoint was the mean 24-hour point-of-care (POC) glucose concentration on day 1. Exploratory end points included proportion of glucose measurements within target glucose range, SD of glucose, and stress hyperglycemia ratio (SHR).
resultsThere was no significant difference in mean POC glucose on day 1 between participants prescribed an individualized insulin regimen and patients receiving a standard body weight-based BBI regimen (10.7±3.4 vs 11.9±3.2 mmol/L, p=0.07). Proportion of glucose measurements within the target glucose range was higher (52.0±4.8 vs 37.0±4.5%, p=0.0007) and SD for glucose lower (3.1±1.5 vs 4.0±1.6, p=0.04) on day 1 of individualized BBI insulin. Over 2 days, there was an increase in glucose SD in both groups, but no significant difference in mean glucose and SHR between groups.
conclusionsIndividualizing a subcutaneous BBI regimen for management of prednisolone-associated hyperglycemia was associated with a modest reduction in mean POC glucose, an increased proportion of blood glucose measurements within the target range, and reduced short-term glycemic variability. TRIAL REGISTRATION NUMBER: ACTRN12618001211257.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.